Intra-Cellular Therapies to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
September 05, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 04, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 CAPLYTA Sales Guidance
August 03, 2023 07:30 ET
|
Intra-Cellular Therapies Inc.
Q2 2023 total revenues increased to $110.8 million, compared to $55.6 million in the same period in 2022 CAPLYTA Q2 2023 net product sales were $110.1 million, compared to $55.1 million for...
Intra-Cellular Therapies to Host Second Quarter 2023 Financial Results Conference Call and Webcast
July 28, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
June 05, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, June 05, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Announces CAPLYTA Data Presentations at the American Society of Clinical Psychopharmacology Annual Meeting
May 31, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 31, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 04, 2023 07:30 ET
|
Intra-Cellular Therapies Inc.
Q1 2023 total revenues of $95.3 million, compared to $35.0 million in the same period in 2022 CAPLYTA Q1 2023 net product sales were $94.7 million, compared to $34.8 million for the same period in...
Intra-Cellular Therapies to Present at Two Upcoming Investor Conferences
May 02, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, May 02, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Host First Quarter 2023 Financial Results Conference Call and Webcast
April 26, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 26, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...
Intra-Cellular Therapies to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023 08:00 ET
|
Intra-Cellular Therapies Inc.
NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central...